BR112022016893A8 - Vacina contra a infecção do vírus da peste suína africana - Google Patents

Vacina contra a infecção do vírus da peste suína africana

Info

Publication number
BR112022016893A8
BR112022016893A8 BR112022016893A BR112022016893A BR112022016893A8 BR 112022016893 A8 BR112022016893 A8 BR 112022016893A8 BR 112022016893 A BR112022016893 A BR 112022016893A BR 112022016893 A BR112022016893 A BR 112022016893A BR 112022016893 A8 BR112022016893 A8 BR 112022016893A8
Authority
BR
Brazil
Prior art keywords
swine fever
african swine
fever virus
vaccine against
virus infection
Prior art date
Application number
BR112022016893A
Other languages
English (en)
Other versions
BR112022016893A2 (pt
Inventor
Dixon Linda
Reis Ana
Rathakrishnan Anusyah
Davis Simon
Jenq Lui Yuan
Ikemizu Shinji
Original Assignee
The Pirbright Inst
The Chancellor Masters And Scholars Of The Univ Of Oxford
Univ Kumamoto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2003292.6A external-priority patent/GB202003292D0/en
Priority claimed from GBGB2003289.2A external-priority patent/GB202003289D0/en
Priority claimed from GBGB2005878.0A external-priority patent/GB202005878D0/en
Priority claimed from GBGB2005880.6A external-priority patent/GB202005880D0/en
Priority claimed from GBGB2013541.4A external-priority patent/GB202013541D0/en
Application filed by The Pirbright Inst, The Chancellor Masters And Scholars Of The Univ Of Oxford, Univ Kumamoto filed Critical The Pirbright Inst
Publication of BR112022016893A2 publication Critical patent/BR112022016893A2/pt
Publication of BR112022016893A8 publication Critical patent/BR112022016893A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12061—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12061—Methods of inactivation or attenuation
    • C12N2710/12062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

VACINA CONTRA A INFECÇÃO DO VÍRUS DA PESTE SUÍNA AFRICANA. A presente invenção se refere a vírus atenuados da Peste Suína Africana. Os vírus atenuados protegem os porcos contra o desafio subsequente com vírus virulentos. A presente invenção também se refere à utilização de tais vírus atenuados para tratar e/ou prevenir a Peste Suína Africana. A invenção também se refere a proteínas EP402R do vírus da Peste Suína Africana compreendendo substituições de aminoácidos particulares, bem como polinucleotídeos que codificam tais proteínas e vírus da Peste Suína Africana compreendendo tais proteínas.
BR112022016893A 2020-03-06 2021-03-05 Vacina contra a infecção do vírus da peste suína africana BR112022016893A8 (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB2003292.6A GB202003292D0 (en) 2020-03-06 2020-03-06 Vaccine
GBGB2003289.2A GB202003289D0 (en) 2020-03-06 2020-03-06 Vaccine
GBGB2005878.0A GB202005878D0 (en) 2020-04-22 2020-04-22 Vaccine
GBGB2005880.6A GB202005880D0 (en) 2020-04-22 2020-04-22 Vaccine
GBGB2013541.4A GB202013541D0 (en) 2020-08-28 2020-08-28 Vaccine
PCT/GB2021/050562 WO2021176236A1 (en) 2020-03-06 2021-03-05 Vaccine against african swine fever virus infection

Publications (2)

Publication Number Publication Date
BR112022016893A2 BR112022016893A2 (pt) 2023-01-24
BR112022016893A8 true BR112022016893A8 (pt) 2023-02-28

Family

ID=74870840

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112022016891A BR112022016891A2 (pt) 2020-03-06 2021-03-05 Vacina contra a infecção por vírus da peste suína africana
BR112022016893A BR112022016893A8 (pt) 2020-03-06 2021-03-05 Vacina contra a infecção do vírus da peste suína africana

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112022016891A BR112022016891A2 (pt) 2020-03-06 2021-03-05 Vacina contra a infecção por vírus da peste suína africana

Country Status (12)

Country Link
US (3) US20230124042A1 (pt)
EP (3) EP4114453A1 (pt)
JP (2) JP2023516713A (pt)
KR (2) KR20230013017A (pt)
CN (3) CN115397463A (pt)
AU (2) AU2021231402A1 (pt)
BR (2) BR112022016891A2 (pt)
CA (2) CA3170043A1 (pt)
CL (2) CL2022002416A1 (pt)
CO (2) CO2022014152A2 (pt)
MX (2) MX2022010373A (pt)
WO (3) WO2021176234A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024031045A2 (en) * 2022-08-04 2024-02-08 Malcolm Thomas Dominant negative antigen approach for prophylactic and post-infection treatment of swine against african swine fever virus
WO2024057048A1 (en) * 2022-09-12 2024-03-21 Consejo Superior De Investigaciones Científicas Attenuated african swine fever virus and use thereof in vaccine compositions
WO2024110451A1 (en) * 2022-11-22 2024-05-30 Intervet International B.V. Attenuated african swine fever virus and use thereof in vaccine compositions
WO2024110453A1 (en) * 2022-11-22 2024-05-30 Gold Standard Diagnostics Madrid, S.A. Method for differentiating asfv infected from asfv vaccinated animals
CN117224669B (zh) * 2023-07-31 2024-07-30 中国农业科学院兰州兽医研究所 非洲猪瘟病毒mgf360-21r蛋白作为免疫诱导剂或者佐剂的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201410971D0 (en) * 2014-06-19 2014-08-06 Pirbright Inst The Vaccine
US9528094B2 (en) * 2014-11-10 2016-12-27 The United States Of America, As Represented By The Secretary Of Agriculture Attenuated African swine fever virus vaccine based in the deletion of MGF genes
CN110551695A (zh) * 2019-08-14 2019-12-10 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 非洲猪瘟病毒四基因缺失弱毒株及其应用

Also Published As

Publication number Publication date
KR20230013016A (ko) 2023-01-26
CN115605223A (zh) 2023-01-13
EP4114455A1 (en) 2023-01-11
EP4114453A1 (en) 2023-01-11
CL2022002416A1 (es) 2023-03-03
CA3170043A1 (en) 2021-09-10
CO2022014256A2 (es) 2022-12-30
MX2022010372A (es) 2023-01-19
AU2021231402A1 (en) 2022-11-03
CO2022014152A2 (es) 2023-02-16
WO2021176234A1 (en) 2021-09-10
BR112022016893A2 (pt) 2023-01-24
US20240293525A1 (en) 2024-09-05
AU2021229654A1 (en) 2022-11-03
CN116133680A (zh) 2023-05-16
EP4114454A1 (en) 2023-01-11
JP2023516713A (ja) 2023-04-20
BR112022016891A2 (pt) 2023-01-24
MX2022010373A (es) 2023-01-19
CN115397463A (zh) 2022-11-25
WO2021176236A1 (en) 2021-09-10
US20230117978A1 (en) 2023-04-20
CA3170058A1 (en) 2021-09-10
WO2021176235A1 (en) 2021-09-10
KR20230013017A (ko) 2023-01-26
JP2023516709A (ja) 2023-04-20
CL2022002412A1 (es) 2023-03-03
US20230124042A1 (en) 2023-04-20

Similar Documents

Publication Publication Date Title
BR112022016893A8 (pt) Vacina contra a infecção do vírus da peste suína africana
BR112023000323A2 (pt) Vacina combinada contra sars-cov-2 e influenza
UY39060A (es) Composiciones y métodos para prevenir y tratar la infección por coronavirus - vacunas sars-cov-2
BR112021024310A2 (pt) Peptidomiméticos para o tratamento de infecções por coronavírus e picornavírus
BR112022019781A2 (pt) Vacina para o coronavírus
BR112018016755A2 (pt) vacina contra o vírus da zica
BR112023020600A2 (pt) Método para tratar ou prevenir uma infecção, e, uso de um composto
CL2016000240A1 (es) Composición inmunogénica de reovirus de peces (prv) que comprende ácido nucleico del prv; polipéptido; virus atenuado o inactivado del prv, uso de la composición inmunogénica que sirve para tratar afecciones de infeción por prv en un animal.
BR112016028816A2 (pt) combinação imunogênica, método para obter uma resposta imunológica específica, uso de uma combinação imunogênica, regime de vacinação para prevenção, redução ou tratamento de infecção por vírus sincicial respiratório, e, kit.
BR112018075440A2 (pt) composições e métodos para prevenir e tratar a infecção por zika vírus
CO2021003931A2 (es) Dosis unitaria de vacuna contra el dengue y administración de esta
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
BRPI0510016B8 (pt) vetor lentiviral recombinante, composição imunogênica e uso dos mesmos como vacina
BR112012021650A2 (pt) "parvovírus recombinante atenuado, vacina para a proteção de animais contra infecção com parvovírus, método para a obtenção de um parvovírus recombinante, e, uso de uma vacina."
BR112022005687A2 (pt) Vacinas contra o hbv e métodos para tratar o hbv
BR112021021637A2 (pt) Vacina de subunidade para tratamento ou prevenção de uma infecção do trato respiratório
BRPI0516963A (pt) ácido nucleico, plasmìdeo, composição veterinária, vacina, métodos de proteção de aves domésticas de colonização por campylobacter e de proteção de um humano de infecção por campylobacter, uso de um ácido nucleico, um plasmìdeo, uma composição, ou uma vacina, e, alimento
EA202091769A1 (ru) Вакцины против вируса гриппа и пути их применения
BR112022016507A2 (pt) Vacinas contra o coronavírus e métodos de uso
BR112022011885A2 (pt) Molécula de ácido nucleico, composição imunogênica, peptídeo, e, métodos para induzir uma resposta imune e para tratar ou prevenir uma patologia
BR112023021654A2 (pt) Vacina contra vírus
UY39464A (es) Composiciones y métodos para la prevención y/o tratamiento de la covid-19
BR112018072298A2 (pt) tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase
BR112022019207A2 (pt) Composições de vacina para coronavírus e métodos de uso das mesmas
CL2023002187A1 (es) Virus para vacuna contra el síndrome respiratorio y reproductivo porcino